{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-002925","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.457906+00:00","generated_at":"2026-05-27T06:37:36.509175+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"medium","headline":"Ocugen posts corporate presentation showing positive retinal gene therapy data","bullets":["Mean change in total atrophy area: treated 0.12±0.36 mm2 vs untreated 0.73±0.26 mm2 (84% less progression).","LL VA decline at 6 months was lower in treated eyes compared to untreated across multiple study cohorts.","Presentation features data from cohorts 006-001, 007-001, and 006-004 suggesting consistent treatment benefit.","Ocugen plans to use this presentation in discussions with investors and analysts on January 29, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-002925","json":"https://secwatch.observer/filing/0001628280-25-002925.json","markdown":"https://secwatch.observer/filing/0001628280-25-002925.md","text":"https://secwatch.observer/filing/0001628280-25-002925.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/0001628280-25-002925-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828025002925/ocgn-20250129.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T06:37:36.509175+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}